Vargatef: new option for lung cancer

Vargatef (nintedanib) is indicated with docetaxel for second-line treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma histology.

Vargatef (nintedanib) capsules are given twice daily.
Vargatef (nintedanib) capsules are given twice daily.

Nintedanib is a triple angiokinase inhibitor which blocks kinase activity at vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and β) and fibroblast growth factor receptors (FGFR 1-3).

Clinical studies

Further information
View Vargatef drug record
Manufacturer: Boehringer Ingelheim

Licensing approval for Vargatef was based on the results of the phase III LUME-Lung 1 study which involved 1,314 adults with locally advanced, metastatic or recurrent NSCLC after one prior line of chemotherapy, including 658 patients with adenocarcinoma.

Patients were randomised to receive nintedanib 200mg (n=655) or placebo (n=659) orally twice daily in combination with intravenous docetaxel 75mg/m2 every 21 days.

The addition of nintedanib to docetaxel therapy resulted in a significant reduction in the risk of progression or death of 21% for the overall population (hazard ratio [HR] 0.79, p=0.0019) and 23% for the adenocarcinoma population (HR 0.77, p=0.0193).

Nintedanib plus docetaxel also significantly improved overall survival in the adenocarcinoma population with a 17% reduction in the risk of death (HR 0.83, p=0.0359) and a median overall survival improvement of 2.3 months versus placebo (12.6 months vs 10.3 months, p=0.0359). The overall survival difference in the total study population did not reach significance.

The most commonly reported adverse effects specific for nintedanib were diarrhoea, raised liver enzymes and vomiting. However, the effect of these on self-reported quality of life were not sufficient to affect the overall treatment benefit observed in the study.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases